inQB8 Medical Technologies LLC and Peijia Medical Limited report on the successful implantation of a first-in-human (FIH) tricuspid valve replacement (TTVR) system in the USA

inQB8 Medical Technologies LLC and Peijia Medical Limited report on the successful implantation of a first-in-human (FIH) tricuspid valve replacement (TTVR) system in the USA

Winchester, Massachusetts. And Suzhou, China, December 5, 2023 /PRNewswire/ — inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)), I announcedSuccessfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient with profuse tricuspid regurgitation (TR) for whom no other treatment was available. TTVR was performed transjugular December 1, 2023For compassionate reasons at UPENN Presbyterian Medical Center by a professor of cardiothoracic surgeon. doctor. Wilson F. SetoInterventional cardiologist Dr. Jan Zhang MD, echocardiologist Dr. Roy, and attending anesthesiologist Dr. Thal. Professor Dr. Fabian Braz from SwitzerlandAnd Lars Sondergaard Doctor of Medicine. They were there to share their experiences. Arshad Qadri, MD. The CEO and CMO of inQB8 monitored the case.

“We have successfully implanted the MonarQ TTV in the appropriate tricuspid region in this high-risk patient. My team and I are grateful and excited to work with Dr. Qadri and his team at inQB8, who have provided this patient with a very exciting MonarQ TTV implant treatment option.”,Dr. Wilson Szeto said. “Due to multiple risk factors and anatomic limitations, conventional tricuspid valve surgery or transcatheter edge-to-edge tricuspid valve repair were not options for this patient. Through careful review and study within our team, we determined that TTVR with MonarQ TTV would relieve symptoms and provide improved quality of life for this very high-risk patient whose only other option was hospice. The valve was successfully implanted resulting in a significant reduction in her profuse tricuspid regurgitation,Dr. Seto added.

“I am honored and excited to work with Dr. Wilson Seto and his team at UPENN Presbyterian Medical Center are in this next chapter of transcatheter valve therapy. The MonarQ TTV has a unique biodynamic tethering system that utilizes and maintains the natural motion of the heart by anchoring the implant to the native leaflets. Biodynamic motion distributes systolic loads, and the multilobular atrial disc helps stabilize the native valve and reduces paravalvular leak. We are very grateful to the patient and her family for agreeing to this new type of valve replacement treatment,” He said Arshad QadriMD, cardiothoracic surgeon and co-founder, CEO, and CMO of inQB8.

“In the past few years, the need for a TTVR solution has become increasingly clear. As Peijia looks to expand its presence globally and build out its core architecture portfolio, our joint investment in inQB8 and MonarQ TTVR technology was a natural choice,” he said. doctor. Michael ChangChairman and CEO of Peijia. “The successful FIH MonarQ implant in the USA represents an exciting step in bringing this life-saving and life-enhancing technology to more and more patients around the world.”

About inQB8

QB8 is a privately owned medical device incubator based in Massachusetts With additional offices in Irvine, California. This is the second collaboration between Dr. Arshad Qadri, MD. and Brent Ratz, MBA, whose partnership began 16 years ago by co-founding CardiAQ Valve Technologies, the world’s first transcatheter mitral valve replacement (TMVR) system. inQB8 is focused on developing new international solutions for major cardiovascular diseases including structural heart problems, aortic disease and heart failure, accelerating projects through prototypes, benchtops and pre-clinical testing until they are ready to be acquired or advanced as a separate standalone cardiovascular startup. -UPS. in June 2021Peijia announced a strategic partnership with inQB8 and agreed to acquire MonarQ TTVR technology, which inQB8 continues to develop on its behalf.

About Beijia

Peijia was founded in 2012 and is headquartered in Suzhou, China. Peijia focuses on the high growth interventional procedural medical devices market in ChinaIt aims to become a world-renowned medical device platform providing comprehensive treatment solutions for structural heart and neurovascular diseases.

Any forward-looking statements are subject to risks and uncertainties such as those described in Peijia’s periodic reports on file with the Hong Kong Stock Exchange. Actual results may differ materially from expected results.

Warning: The MonarQ TTVR system is in the early stages of development. It will not be available for clinical trials until further notice and is not available for sale.

Source: Pegea Medical

    (Tags for translation)Peijia Medical

You may also like...

Leave a Reply